Streetbeat News

Stock Prices

CRM

Salesforce (CRM) has been analyzed by 28 analysts, showing a shift towards more bullish sentiments with an increase in the average 12-month price target to $287.18 from $264.00. Analyst actions include ratings adjustments and price target changes, reflecting responses to market conditions and Salesforce's performance. The company's financial overview indicates a strong market position with solid revenue growth and net margin, despite challenges in ROE and ROA.

Portfolio Pulse from Benzinga Insights

February 12, 2024 | 2:00 pm

WEX

Over the past 15 years, WEX (NYSE:WEX) has significantly outperformed the market, with an average annual return of 46.36%, turning a $100 investment into $30,305.71. The company currently has a market capitalization of $9.07 billion.

Portfolio Pulse from Benzinga Insights

February 12, 2024 | 2:00 pm

CBAY

CymaBay Therapeutics shares have resumed trading, indicating a potential shift in market dynamics for the company.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 2:00 pm

LRMR

Larimar Therapeutics shares dropped following the announcement of top-line data from the Phase 2 study of nomlabofusp in Friedreich's ataxia patients.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 1:58 pm

CTLT

LLY

NVO

Novo Nordisk (NVO) and Eli Lilly (LLY) are addressing the supply shortage of their weight loss drugs, Wegovy and Zepbound, amid soaring demand. Novo Nordisk has doubled the availability of Wegovy's lower doses and acquired three manufacturing sites for $11 billion to boost production. Eli Lilly has doubled its production capacity for incretin drugs and plans further expansion. Both companies are exploring alternative drug forms to meet demand, with Eli Lilly launching Mounjaro in a new delivery device outside the U.S. LLY shares slightly up, NVO shares down in premarket trading.

Portfolio Pulse from Vandana Singh

February 12, 2024 | 1:57 pm

CAT

IWM

JEPQ

MPC

On CNBC's 'Halftime Report Final Trades,' experts highlighted their top stock picks, including JPMorgan Nasdaq Equity Premium Income ETF (JEPQ), Marathon Petroleum Corporation (MPC), iShares Russell 2000 ETF (IWM), and Caterpillar Inc. (CAT). Marathon Petroleum reported better-than-expected Q4 results with revenue of $36.82 billion and adjusted EPS of $3.98. Caterpillar also exceeded Q4 earnings expectations with revenue of $17.07 billion and adjusted EPS of $5.23. Following Caterpillar's earnings release, several firms raised their price targets on the stock. The mentioned assets experienced varied price movements on Friday.

Portfolio Pulse from Avi Kapoor

February 12, 2024 | 1:55 pm

ANTX

AN2 Therapeutics announced a voluntary pause in the Phase 3 part of their Phase 2/3 pivotal clinical trial for epetraborole in treatment-refractory MAC lung disease, leading to a decrease in their stock price.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 1:55 pm

SGLY

Trading for SGLY was halted and then resumed at 8:55 AM ET, with updates on quotation resumption times provided.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 1:55 pm

XPO

XPO shares have declined following a downgrade by Morgan Stanley from Equal-Weight to Underweight.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 1:51 pm

TEVA

Teva Pharmaceuticals' stock price increased following an upgrade by Piper Sandler from Neutral to Overweight, with a raised price target from $12 to $19.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 1:49 pm